Tag Archive for: biotech

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

/in

AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry. Read more…

Read more

World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London

/in

BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial College London (ICL) to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research from world-class scientists to benefit people and society. Read more…

Read more

BII announces new cohort of companies entering the Venture Lab program

/in

BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – all strategically aligned with BII’s focus on developing ground-breaking scientific initiatives […]

Read more

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

/in

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance […]

Read more

Ariceum Therapeutics Launches with €25M Series A

/in

Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News

Read more
© Optimum Strategic Communications.